NCT05469737: A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 230 planned
- Started
- 14 Dec 2022
- Primary completion
- 31 Jul 2028
- Arms
- Part I - Oral-Aza (Dose 1), Part I - Oral-Aza (Dose 2), Part II - Oral-Aza (RP3D)
- Results
- None posted
- 22 Jul 2022: Trial registered
- 14 Dec 2022: Trial started